U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015801) titled 'CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency' on May 22.

Brief Summary: Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Cytomegalovirus Viremia Cytomegalovirus Pneumonia T-Lymphocyte Immunodeficiency

Intervention: BIOLOGICAL: CMV-VST

30-40 x 10^3 viable CD3+ cells/kg

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: University of Calgary

Published by HT Digital C...